News|Articles|July 31, 2026
The 3 Perspectives of 340B: Legal, Safety-Net, and Purchaser
Author(s)Brian Nowosielski
Based on discussions from a recent webinar debate on the 340B Drug Pricing Program, we’re revealing how differently key stakeholders see a program that pharmacists participate in every day.
Advertisement
Advertisement
When health policy experts squared off in a recent webinar, titled “The Great 340B Debate,” the disagreement was not about whether safety-net care matters; it was about whether 340B is the right vehicle for funding it. For pharmacists managing 340B workflows daily, understanding the full landscape means hearing more than one side.
Advertisement
Advertisement
